Investigation of resveratrol as a xanthine oxidase inhibitor: Mechanistic insights and therapeutic implications for gout and hyperuricemia

被引:0
|
作者
Chen, Jianmin [1 ,2 ,3 ]
Chen, Juan [1 ]
Feng, Baozhu [1 ]
Ning, Meilian [1 ]
Wu, Wanhui [1 ]
Zou, Shiqi [1 ]
机构
[1] Putian Univ, Sch Pharm, Putian 351100, Fujian, Peoples R China
[2] Putian Univ, Fujian Prov Univ, Key Lab Pharmaceut Anal, Putian, Fujian, Peoples R China
[3] Putian Univ, Fujian Prov Univ, Lab Med, Putian, Fujian, Peoples R China
基金
中国国家自然科学基金;
关键词
allopurinol; hyperuricemia; resveratrol; uric acid; xanthine oxidase; URIC-ACID; IN-VITRO; OXIDOREDUCTASE; TOPIROXOSTAT; TYROSINASE;
D O I
10.1002/bab.2690
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gout predominantly stems from hyperuricemia, precipitating the accumulation of urate crystals and consequent joint inflammation, swelling, and pain, thereby compromising the quality of life and presenting a formidable medical dilemma. Although conventional treatments like allopurinol and febuxostat target uric acid reduction via xanthine oxidase (XO) inhibition, they often entail adverse effects, prompting the exploration of safer alternatives. Resveratrol, a polyphenolic compound abundant in fruits and vegetables, has emerged as a potential XO inhibitor. However, its precise inhibitory mechanisms remain poorly understood. This study aims to comprehensively investigate resveratrol's XO inhibition through mechanistic insights, molecular docking simulations, animal model experiments, and biochemical analysis, contributing valuable insights to the development of novel therapeutics for hyperuricemia and gout.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Therapeutic effects and mechanisms of N-(9,10-anthraquinone-2-ylcarbonyl) xanthine oxidase inhibitors on hyperuricemia
    Gao, Tianshu
    Xu, Jin
    Xiao, Yuxiao
    Li, Jiaqi
    Hu, Weifeng
    Su, Xiaoyu
    Shen, Xudong
    Yu, Wan
    Chen, Zhen
    Huang, Baosheng
    Li, Honglei
    Wang, Xing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] Structural and biochemical insights into a hyperthermostable urate oxidase from Thermobispora bispora for hyperuricemia and gout therapy
    Chiu, Yi-Chih
    Hsu, Ting-Syuan
    Huang, Chen-Yu
    Hsu, Chun-Hua
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2021, 188 (188) : 914 - 923
  • [33] Natural Xanthine Oxidase Inhibitor 5-O-Caffeoylshikimic Acid Ameliorates Kidney Injury Caused by Hyperuricemia in Mice
    Zhang, Dong
    Zhao, Mojiao
    Li, Yumei
    Zhang, Dafang
    Yang, Yong
    Li, Lijing
    MOLECULES, 2021, 26 (23):
  • [34] Insights from multispectral and molecular docking investigation on the xanthine oxidase inhibition by 1,4-dicaffeoylquinic acid
    Cao, Weiwei
    Fang, Yajing
    Wu, Ting
    Liang, Fuqiang
    Cheng, Yuxin
    Salah, Mahmoud
    Pan, Siyi
    Xu, Xiaoyun
    JOURNAL OF MOLECULAR STRUCTURE, 2020, 1219
  • [35] Effect of the Xanthine Oxidase Inhibitor Febuxostat on the Cardio-Ankle Vascular Index in Asymptomatic Patients with Hyperuricemia and Liver Dysfunction: A Sub-Analysis of the PRIZE Study
    Kawachi, Yusuke
    Fujishima, Yuya
    Nishizawa, Hitoshi
    Tanaka, Atsushi
    Yoshida, Hisako
    Niwano, Shinichi
    Suzuki, Makoto
    Shimomura, Iichiro
    Node, Koichi
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2024, : 474 - 490
  • [36] Physicochemical features and structural analysis of xanthine oxidase as a potential therapeutic target to prevent gout
    Nawaz, Muhammad Zohaib
    Ain, Qurat-ul
    Zahid, Sara
    Zulfiqar, Tooba
    Attique, Syed Awais
    Bilal, Muhammad
    Alghamdi, Huda Ahmed
    Yan, Wei
    Iqbal, Hafiz M. N.
    JOURNAL OF RADIATION RESEARCH AND APPLIED SCIENCES, 2020, 13 (01) : 616 - 628
  • [37] Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications
    Sattui, Sebastian E.
    Gaffo, Angelo L.
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2016, 8 (04) : 145 - 159
  • [38] Placebo-Controlled, Double-Blind Study of the Non-Purine-Selective Xanthine Oxidase Inhibitor Febuxostat (TMX-67) in Patients With Hyperuricemia Including Those With Gout in Japan
    Naoyuki, Kamatani
    Shin, Fujimori
    Toshikazu, Hada
    Tatsuo, Hosoya
    Kenjiro, Kohri
    Toshitaka, Nakamura
    Takanori, Ueda
    Tetsuya, Yamamoto
    Hisashi, Yamanaka
    Yuji, Matsuzawa
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (04) : S19 - S26
  • [39] Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor raloxifene: Implications for identifying molybdopterin nitrite reductases
    Weidert, E. R.
    Schoenborn, S. O.
    Cantu-Medellin, N.
    Choughule, K. V.
    Jones, J. P.
    Kelley, E. E.
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2014, 37 : 41 - 45
  • [40] The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol—study protocol
    Masashi Sakuma
    Shigeru Toyoda
    Takuo Arikawa
    Yota Koyabu
    Toru Kato
    Taichi Adachi
    Hideaki Suwa
    Jun-ichi Narita
    Koetsu Anraku
    Kimihiko Ishimura
    Fumitake Yamauchi
    Yasunori Sato
    Teruo Inoue
    Clinical and Experimental Nephrology, 2018, 22 : 1379 - 1386